



Absence of the *mecC* gene in methicillin-resistant *Staphylococcus aureus* isolated from various clinical samples: The first multi-centered study in Turkey

Aytekin Cikman^a, Merve Aydin^{a,b,*}, Baris Gulhan^a, Faruk Karakecili^c,
Muhammet G. Kurtoglu^d, Serife Yuksekkaya^e, Mehmet Parlak^f, Bilge S. Gultepe^g,
Aysegul C. Cicek^h, Fulya B. Bilmanⁱ, Ihsan H. Ciftci^j, Murat Kara^a, Selahattin Atmaca^k,
Tuncer Ozekinci^k

^a Erzincan Binali Yildirim University, Faculty of Medicine, Department of Medical Microbiology, Erzincan, Turkey

^b KTO Karatay University, Faculty of Medicine, Department of Medical Microbiology, Konya, Turkey

^c Erzincan Binali Yildirim University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzincan, Turkey

^d Abant Izzet Baysal University, Faculty of Medicine, Department of Medical Microbiology, Bolu, Turkey

^e Konya Training and Research Hospital, Microbiology Laboratory, Konya, Turkey

^f Yuzuncu Yil University, Faculty of Medicine, Department of Medical Microbiology, Van, Turkey

^g Bezmi-Alem University, Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey

^h Recep Tayyip Erdogan University, Faculty of Medicine, Department of Medical Microbiology, Rize, Turkey

ⁱ Izmir Menemen State Hospital, Department of Medical Microbiology, Izmir, Turkey

^j Sakarya University, Faculty of Medicine, Department of Medical Microbiology, Sakarya, Turkey

^k Dicle University, Faculty of Medicine, Department of Medical Microbiology, Diyarbakir, Turkey

ARTICLE INFO

Article history:

Received 24 October 2018

Received in revised form 21 January 2019

Accepted 23 January 2019

Keywords:

Methicillin resistance

Staphylococcus aureus

mecC

mecA

Turkey

ABSTRACT

Background: *mecA* is a predefined gene causing methicillin resistance in *Staphylococcus aureus* (*S. aureus*) isolates; however, it has been shown that some methicillin-resistant *S. aureus* (MRSA) strains do not carry this gene. Recently, in isolates found to be MRSA-positive but *mecA*-negative, a new resistance gene called *mecC*, which is a homolog of *mecA*, has been reported. This study aimed to investigate the *mecC* and *mecA* genes in MRSA strains isolated from different geographic regions in Turkey.

Methods: The sample of the study consisted of 494 MRSA strains isolated from seven geographical regions in Turkey between 2013 and 2016. The strains were obtained from 17 centers, comprising 13 university hospitals, three education and research hospitals, and one state hospital. Methicillin resistance in *S. aureus* strains was determined using the agar disk diffusion method with a cefoxitin disk and the agar dilution method with oxacillin. The *mecC* and *mecA* genes in MRSA strains was investigated by Polymerase Chain Reaction (PCR).

Results: Of the MRSA strains investigated, 47.9% were isolated from intensive care units. Concerning sample type, 36.7% were detected in the respiratory tract (tracheal aspirate, sputum, etc.), 24.8% in blood, 18.7% in skin and soft tissues, 9.3% in nasal swabs, 5.4% in urine, 4.1% in ears, and 1% in sterile body fluid. Using PCR, *mecC* was not identified in any of the *S. aureus* strains isolated from different clinical microbiology laboratories. *mecA* gene positivity was found in 315 of the MRSA strains (63.8%). Staphylococcal Cassette Chromosome *mec* (SCC*mec*) type was identified in 232 strains (46.9%), of which 136 (58.7%) were type II, 75 (32.4%) were type IV, 12 (5.1%) were type IIb, six (2.5%) were type I, and three (1.3%) were type III.

Abbreviations: *S. aureus*, *Staphylococcus aureus*; MRSA, methicillin-resistant *S. aureus*; PCR, polymerase chain reaction; SCC*mec*, staphylococcal cassette chromosome *mec*; PBP 2a, penicillin-binding protein 2a; SCCs, staphylococcal cassette chromosomes; CLSI, clinical and laboratory standards institute; PBS, phosphate buffer saline; SPSS, statistical package for the social sciences; TBE, tris-borate-EDTA buffer; MSSA, methicillin-susceptible *Staphylococcus aureus*; HA-MRSA, hospital-acquired MRSA; CA-MRSA, community-acquired MRSA.

* Corresponding author at: KTO Karatay University, Faculty of Medicine, Department of Medical Microbiology, 42020 Konya, Turkey.

E-mail address: merve.aydin@karatay.edu.tr (M. Aydin).

<https://doi.org/10.1016/j.jiph.2019.01.063>

1876-0341/© 2019 The Authors. Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusion: This is the first multi-centered study to investigate MRSA strains isolated from different regions in Turkey. The *mecC* gene was not detected in any of the MRSA strains. We believe that this study will constitute an important basis for monitoring possible future changes.

© 2019 The Authors. Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Staphylococcus aureus primarily causes skin and soft tissue infections, as well as other serious infections, such as pneumonia, osteomyelitis, meningitis, and endocarditis [1]. While *S. aureus* strains used to be only resistant to penicillin and its derivatives through the mechanism of β -lactamase production, they developed resistance to all β -lactam antibiotics as a result of the change in penicillin-binding protein 2a (PBP 2a) found in their genomes [2,3].

Methicillin-resistant *S. aureus* (MRSA) strains produce an altered penicillin-binding protein (PBP 2a) encoded by *mecA*, a gene located within a mobile genetic element called the Staphylococcal Chromosome Cassette *mec* (SCC*mec*) [4,5]. SCC*mec* elements are highly diverse in their structural organization and genetic content and have been classified into types from type I to type XIII [6,7].

In 2005, Livestock-Associated MRSA (LA-MRSA) CC398 was detected for the first time in pigs and pig farmers. From this period onwards, it was determined that the pig population was a reservoir for LA-MRSA, but LA-MRSA was also found in a wide range of animals such as chickens, horses, sheep, goats, calves, and dairy cattle [8–10]. In a study on cattle mastitis in the United Kingdom (UK), an oxacillin- and methicillin-resistant *S. aureus* isolate was phenotypically identified in a sample obtained from a milk tank [11]. However, it was determined that this isolate did not carry the *mecA* gene. The genomic sequence analysis of this isolate, LGA251, revealed that it carried a *mecA* homolog (*mecA*_{LGA251}) with approximately 69% similarity to the classical *mecA* gene, and this newly identified gene encoded a protein with approximately 63% similarity to the PBP 2a protein and was named *mecC* in 2012 [12].

mecC MRSA has been reported in a wide range of other host species, including livestock, wildlife and companion animals in many European countries. As in human isolates, those isolated from animals are associated more with the clonal complex 130 (CC130) and with ST425 to a lesser degree. Therefore, this lineage seems to have a broad host tropism [13]. Several studies have shown that *mecC*-positive MRSA is relatively common in dairy cattle, suggesting that cattle provide an infection reservoir and farmers in contact with dairy cattle may be at risk of acquiring these isolates [10,14,15]. Furthermore, researchers using whole-genome sequencing have reported evidence of zoonotic transmission of *mecC*-positive MRSA from cattle to humans [16]. In addition, MRSA carrying the *mecC* gene was found in sheep, which might be considered as another reservoir [15]. *mecC* MRSA is currently rare in humans, but there are interesting geographical differences in terms of prevalence; in particular, the latest increase in prevalence in Denmark underlines the need to monitor *mecC* MRSA [10,16]. However, to the best of our knowledge, there is no comprehensive study that examined the *mecC* gene in Turkey. Therefore, this study aimed to explore the presence of the *mecC* gene in MRSA strains isolated from different geographic regions in Turkey.

Materials and methods

Study area and bacterial isolates

There are seven geographical regions in Turkey. The sample of this study consisted of 494 MRSA strains isolated from all seven regions between 2013 and 2016. Of these strains, 120 were

obtained from Central Anatolia, 111 from Black Sea, 102 from Marmara, 80 from Eastern Anatolia, 47 Aegean, 18 from South East Anatolia, and 16 from Mediterranean.

The study was carried out in Erzincan Binali Yıldırım University Mengücek Gazi Training and Research Hospital Microbiology Laboratory. The strains were transferred to our laboratory in cryobeads in accordance with cold chain transportation rules and stored at -80°C until analysis. The cryobeads were thawed at room temperature before enrichment in tryptic soy broth and cultured onto a blood agar.

Antibiotic susceptibility testing

The methicillin resistance was determined using the Kirby-Bauer disk diffusion method with a cefoxitin disk (30 μg , Oxoid, UK) and the agar dilution method with oxacillin (Sigma-Aldrich, Germany) according to the Clinical and Laboratory Standards Institute (CLSI) standards [17]. For the cefoxitin disk diffusion assay, a suspension of colonies was grown for 24 h and adjusted to give a turbidity equivalent to 0.5 McFarland standard. The bacterial suspension was spread over the surface of the Mueller–Hinton agar medium (Oxoid, UK) by swabbing, and cefoxitin disks were placed on the surface of the agar. The plates were incubated at 37°C for 16–18 h; then, the zone diameters were measured, and the isolates with a zone diameter of ≤ 21 mm for cefoxitin were considered to be methicillin-resistant. For the oxacillin agar dilution assay, 0.5 McFarland standards were prepared from freshly grown bacterial cultures. This suspension was inoculated onto the Mueller Hinton agar medium (+4% NaCl) containing 6 $\mu\text{g}/\text{ml}$ oxacillin and incubated at 37°C for 24 h. Testing at temperatures above 35°C may not detect MRSA. >1 colony growth was considered oxacillin-resistant [17].

DNA isolation

The isolates were subcultured on trypticase soya agar plates (bioMérieux, France) prior to DNA extraction. For DNA extraction, one colony was suspended on 500 μl of sterile phosphate buffer saline (PBS) (pH: 7.2). The bacterial cells were harvested by centrifugation at $3000 \times g$ for 10 min, and the pellet was resuspended in 350 μl TE buffer [10 mM Tris chloride, 1 mM EDTA (pH 8.0)] containing nystatin (100 $\mu\text{g}/\text{ml}$) (Sigma, St Louis, MO, USA) and incubated at 37°C for 1 h, vortexing every 15 min. Then, 350 μl of 10% sodium dodecyl sulfate (SDS) containing proteinase K (100 $\mu\text{g}/\text{ml}$) (Vivantis Technologies, Malaysia) was added and incubated at 37°C for 2 h, vortexing every 15 min. Next, DNA was extracted using the phenol/chloroform method as described by Sambrook and Russell [18]. The DNA was eluted in 100 μl of TE buffer [10 mM Tris chloride–1 mM EDTA (pH 8.0)], and stored at -20°C until use.

Multiplex PCR for SCC*mec* typing

The cycling conditions and primers as described by Oliveira and de Lencastre [19] were used to detect the *mecA* gene and SCC*mec* types (I–IV) (Table 1). The primer sets used for the assignment of the *mecA* gene and SCC*mec* types are listed in Table 1. The multiplex PCR was performed in a 50 μl volume: $1 \times$ PCR buffer; 200 μM (each) dNTP; 200 nM concentrations of primers KDP F1, KDP R1,

Table 1
Primers used in multiplex PCR [17].

Locus	Primer	Oligonucleotide sequence (5'-3')	Location	Amplicon size (bp)	Specificity (SCCmec type)
A	CIF2 F2	5'-TTCGAGTTGCTGATGAAGAAGG-3'	18398-18419	495	I
	CIF2 R2	5'-ATTACCACAAGGACTACCAGC-3'	18892-18871		
B	KDP F1	5'-AATCATCTGCCATTGGTGATGC-3'	10445-10467	284	II
	KDP R1	5'-CGAATGAAGTGAAAGAAAGTGG-3'	10728-10707		
C	MECI P2	5'-ATCAAGACTTGCATTAGGC-3'	42428-42447	209	II, III
	MECI P3	5'-GCGGTTTCAATTCACITGTC-3'	42636-42617		
D	DCS F2	5'-CATCTATGATAGCTTGGTC-3'	38011-37992	342	I, II, IV
	DCS R1	5'-CTAATCATAGCCATGACCG-3'	37670-37689		
E	RIF4 F3	5'-GTGATTGTTCGAGATATGTGG-3'	45587-45607	243	III
	RIF4 R9	5'-CGCTTTATCTGTATCTATCGC-3'	45829-45809		
F	RIF5 F10	5'-TTCTTAAGTACACGCTGAATCG-3'	59573-59594	414	III
	RIF5 R13	5'-GTCACAGTAATTCATCAATGC-3'	59986-59965		
G	IS431 P4	5'-CAGGTCTCTTCAGATCTACG-3'	49963-49982	381	
	pUB110 R1	5'-GAGCCATAAACACCAATAGCC-3'	50343-50323		
H	IS431 P4	5'-CAGGTCTCTTCAGATCTACG-3'	29654-29673	303	
	pT181 R1	5'-GAAGAATGGGGAAGCTTCAC-3'	29976-29956		
<i>mecA</i>	MECA P4	5'-TCCAGATTACAACCTCACCAGG-3'	1190-1211	162	Internal control
	MECA P7	5'-CCACTTCATATCTGTAAACG-3'	1351-1332		

RIF4 F3, and RIF4 R9; 400 nM concentrations of primers CIF2 F2, CIF2 R2, MECI P2, MECI P3, RIF5 F10, RIF5 R13, pUB110 R1, and pT181 R1; 800 nM concentrations of primers DCS F2, DCS R2, MECA P4, MECA P7, and IS431 P4; 1.5 U of Taq DNA Polymerase (Vivantis Technologies, Malaysia); and approximately 5 ng of template DNA.

PCR was carried out in a DNA Thermal Cycler CFX 96 (Bio-Rad, Hercules, CA) with the following conditions: predenaturation for 4 min at 94 °C, 30 cycles of 94 °C for 30 s, 53 °C for 30 s, and 72 °C for 1 min; post-extension for 4 min at 72 °C; and soaking at 4 °C. The PCR products were electrophoresed on 2% agarose gel in 0.5 × Tris-borate-EDTA (TBE) buffer (Vivantis Technologies, Malaysia) and stained with ethidium bromide (0.5 µg/ml). *S. aureus* ATCC 43300 was used as the positive control strain.

Detection of the *mecC* gene

For the detection of the *mecC* gene by PCR, we used the following primers described by Stegger et al. [20] as follows: 5'-GAA AAA AAG GCT TAG AAC GCC TC-3' (forward) and 5'-GAA GAT CTT TTC CGT TTT CAG C-3' (reverse). Amplification was performed with the following conditions: 15 min at 94 °C, followed by 30 cycles of 30 s at 94 °C, 1 min at 59 °C, and 1 min at 72 °C, with a final 10 min elongation step at 72 °C. The PCR products were electrophoresed on 2% agarose gel in 0.5 × Tris-borate-EDTA (TBE) buffer (Vivantis Technologies, Malaysia) and stained with ethidium bromide (0.5 µg/ml). *S. aureus* NCTC 13552 was used as the positive control strain.

Statistical analysis

The Statistical Package for the Social Sciences (SPSS, IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY) was used to evaluate the data. Continuous variables were summarized as means ± standard deviation, and categorical variables as n (%).

Results

The *S. aureus*-isolated patients were between the ages of 1 and 92, and the mean age was 54.8 ± 2.4 years. Of the strains, 269 (54.5%) were isolated from male patients and 225 (45.5%) from females.

Table 2
Distribution of *S. aureus* strains by clinic.

Clinic	Total (n/%)
Intensive care unit	237 (47.9)
Internal medicine	53 (10.8)
Pediatric service	40 (8.1)
Orthopedics	35 (7.0)
Otorhinolaryngology	23 (4.6)
Infectious diseases	21 (4.3)
Dermatology	17 (3.5)
Urology	16 (3.3)
Pulmonary diseases	16 (3.3)
Other	36 (7.2)
Total	494 (100)

Table 3
Distribution of *S. aureus* strains by type of sample.

Type of Sample	Total (n/%)
Respiratory (tracheal aspirate, sputum, etc.)	181 (36.7)
Blood	123 (24.8)
Skin and soft tissue	92 (18.7)
Nose	46 (9.3)
Urine	27 (5.4)
Ears	20 (4.1)
Sterile body fluid	5 (1.0)
Total	494 (100)

Fig. 2 and Table 2 present the distributions of the MRSA strains according to the geographical regions and clinics from which they were isolated, respectively. Most of the MRSA strains were isolated from intensive care units (47.9%), followed by internal medicine (10.8%), pediatrics (8.1%), and orthopedics and traumatology services (7%).

Concerning the type of samples, most MRSA strains were isolated from the respiratory tract (sputum, tracheal aspirate, bronchoalveolar lavage etc.), blood, skin and soft tissues. Table 3 presents the distribution of all MRSA strains by type of sample.

All isolates were reported to be phenotypically resistant to oxacillin and cefoxitin, and identified as MRSA by diagnostic laboratory analysis. In this study, the multiplex PCR did not reveal the presence of *mecC* gene in any of the 494 MRSA isolates obtained from all seven geographical regions in Turkey. The *mecA* gene was positive in 315 of the MRSA strains (63.8%) and the SCCmec type was




Fig. 1. Representative gel demonstrating the expected PCR products for SCCmec types. I–IV. Lanes M: DNA molecular size marker (VC 100 bp Plus DNA Ladder, Vivantis Technologies, Malaysia).



Fig. 2. Distribution of the investigated *S. aureus* strains and SCCmec types by geographical region.

identified in 232 strains (46.9%) as follows: type II in 136 (58.7%), type IV in 75 (32.4%), type IIIb in 12 (5.1%), type I in six (2.5%), and type III in three (1.3%) (Fig. 1). Fig. 2 presents the distribution of MRSA SCCmec types by geographical region.

Discussion

MRSA, is a major pathogen associated with severe nosocomial infections due to its multidrug resistance that limits treatment options. In addition to being resistant to all β -lactams, MRSA can also show resistance to antimicrobials included in macrolide, quinolone, tetracycline, lincosamide and aminoglycoside groups [21]. Therefore, the diagnosis and detection of MRSA is necessary and important for the selection of appropriate treatment for patients [22].

MRSA isolates are detected by the disk diffusion method using a cefoxitin disk or the agar dilution method with oxacillin. Oxacillin maintains its activity during storage better than methicillin and is more likely to detect heteroresistant strains. However, cefoxitin is an even better inducer of the *mecA* gene, and tests using cefoxitin

provide more reproducible and accurate results than those with oxacillin. In addition, CLSI, recommends the cefoxitin disk screen test. However, detecting the *mecA* gene by PCR is the gold standard method [17,23,24]. To date, 13 different SCCmec types have been defined [7]. The SCCmec type of hospital-acquired MRSA (HA-MRSA) differs from that of community-acquired MRSA (CA-MRSA) [25,26], with types I, II and III being mostly found in HA-MRSA and types IV and V in CA-MRSA [25–27].

Several studies conducted in Turkey showed that SCCmec type III was the most common. For example, Akoğlu et al. [28] reported SCCmec type III in 61.8%, type IIIb in 34.5%, and type IV in 2.7% of HA-MRSA strains. Kilic et al. [29] demonstrated that SCCmec type III was predominant (82.1%) in a tertiary care facility over a period of four years. In another epidemiological study conducted between 2006 and 2008, Bozdoğan et al. investigated the SCCmec types of 397 MRSA strains isolated from different geographical regions in Turkey and identified type III in 91.4% and type IV in 7.6% of the samples [30].

In this study, the SCCmec type of 232 MRSA strains was defined. Unlike many studies undertaken in Turkey, we found SCCmec type II

to be the most common type. In previous studies, the SCCmec type of MRSA strains was shown to vary between countries, between different centers in the same country, or even in the same region over time. For example, of the MRSA strains isolated from Japan between 1979 and 1985, 53.6% were reported to be of SCCmec type IV, 22.7% type I, and 21.6% type II. However, after the 1990s, sequence type 5 (ST5)-SCCmec type II was found to be the dominant clinical MRSA strain in Japanese hospitals [31]. In the current study, 47.9% of the strains were isolated from intensive care units, 36.7% from respiratory samples, and 24.8% from blood samples. We consider that our results differing from those of other studies conducted in Turkey may be due to the differences in the study period and patient groups.

It was previously reported that in MRSA strains that did not carry the *mecA* gene, methicillin resistance was caused by the *mecC* gene [15]. *mecC* was first isolated from a bulk tank milk sample in southwest England [11]. The discovery of MRSA carrying the *mecC* gene has led to the investigation of the source and epidemiology of these isolates in many countries. In a previous study, *mecC* was identified in various samples obtained from 14 different local and wild animal species in 13 European countries [13]. Furthermore, *mecC*-positive *S. aureus* isolates were not only detected in animal species, but also in humans. Although these isolates are less common among humans, MRSA strains carrying the *mecC* gene may become problematic for public health since phenotypic and genotypic tests are not sufficient to properly detect this gene [32].

In a study conducted in Denmark between 2003 and 2011, the *mecC* positivity was reported to be 1.5%, and the authors noted an increase in *mecC*-positive samples from 1.9% in 2010 to 2.8% in 2011 [10]. In Germany, the presence of *mecC* was investigated in 1604 MRSA strains isolated in 2004 and 2005, and 1603 strains isolated in 2010 and 2011, and only one isolate (0.06%) was found to be *mecC*-positive for each period [33].

In studies conducted in various countries, *mecC* was not detected in 102 MRSA strains isolated from wounded military personnel in the United States of America (USA) between 2009 and 2011 [34], 34 MRSA strains isolated from a dental clinic in Egypt [35], and any of the 500 *S. aureus* isolates collected in the UK in 2012 and 2013 [36].

In Turkey, only one study was found to have investigated the *mecC* gene in MRSA strains isolated from humans. In that study, Kılıç et al. [37] isolated 1177 MSSA (Methicillin-Susceptible *S. aureus*) and 523 MRSA strains isolated from various clinical samples in a hospital between 2007 and 2014, and reported that *mecC* was not present in any of the samples.

Similarly, in the current study that explored the presence of the *mecC* gene in a selected number of strains collected from all geographical regions in Turkey, we did not identify any MRSA isolate that carried this gene.

Recently, during routine MRSA screening in an *S. aureus* isolate that tested negative for *mecA* and *mecC* but thought to be methicillin resistant, Becker et al. discovered a plasmid carrying the *mecB* gene. The isolate had been obtained from the nasal-throat swab of a 67-year-old cardiology patient with no sign of infection. A comparative analysis of the *mecB* DNA of *S. aureus* revealed that *Macroccoccus caseolyticus* had 100% sequence identity with the reported *mecB* gene, and thus belonged to the same allotype. The *mecB* homolog of *S. aureus* shows a 60% nucleotide sequence similarity to the originally identified *mecA* gene of *S. aureus* N315. As in the *mecA* and *mecC* genes, *mecB* in *S. aureus* results in methicillin resistance, and therefore the strains it carries should be accurately identified as MRSA, rather than as MSSA. This can be achieved using antibiotic susceptibility testing. However, the PCR method with *mecB*-specific primers should also be undertaken for the accurate identification of MRSA strains [38,39].

The limitation of the current study was that the presence of *mecA* and *mecC* genes was not detected in the 179 isolates that were found to have phenotypic methicillin resistance. The absence of the detection of *mecA* and *mecC* genes in these isolates may be related to the PCR method used or the presence of a different *mec* gene (*mecB*).

In conclusion, certain questions remain unanswered about the *mecC* gene, concerning the origin of the *mec* homolog, the actual distribution and prevalence in animal populations and human beings, and the real zoonotic potential of the staphylococcal isolates harboring *mecC*. Our study was the first multi-centered study that investigated the presence of the *mecC* gene in MRSA strains isolated from all geographical regions in Turkey. To date, no MRSA strain isolated from human beings in Turkey has been reported to carry the *mecC* gene. However, considering that MRSA isolates with the *mecC* gene were found to have rapidly spread across Europe after the identification of farm animals as reservoirs, it is very likely that this gene will also be detected in Turkey in the near future. We believe that this study will provide an important basis for monitoring possible future changes. We also consider that there is a need for further studies to investigate the types of *mecA* in MRSA strains.

Funding

No funding sources.

Competing interests

None declared.

Ethical approval

This study was approved by the Clinical Research Ethics Board of Erzincan Binali Yildirim University, Faculty of Medicine (No: 01/04, Date: 06.02.2015).

Authors' contributions

The conception and design of the study: AC. Collected isolates: AC, MA, BG, FK, MGK, SY, MP, BG, ACC, FBB, IHC, MK, SA, TO. Acquisition of data: AC, MA, BG. Analysis and interpretation of data: AC, MA. Critical revision of the manuscript for important intellectual content and final approval of the manuscript: AC, MA. All authors read and approved the final manuscript.

Acknowledgements

This study was financially supported by the Scientific Research and Project Unit of Erzincan Binali Yildirim University (Project No: SAG-A-240215-0121). This research was presented as a poster in the 4th National Clinical Microbiology Congress in Antalya, Turkey, 2017.

References

- [1] Purrello SM, Garau J, Giamarellos E, Mazzei T, Pea F, Soriano A, et al. Methicillin-resistant *Staphylococcus aureus* infections: a review of the currently available treatment options. J Glob Antimicrob Resist 2016;7:178–86, <http://dx.doi.org/10.1016/j.jgar.2016.07.010>.
- [2] Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in *Staphylococci*. Epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997;11(4):813–49, [http://dx.doi.org/10.1016/S0891-5520\(05\)70392-5](http://dx.doi.org/10.1016/S0891-5520(05)70392-5).
- [3] Archer GL. *Staphylococcus aureus*: a well-armed pathogen. Clin Infect Dis 1998;26(5):1179–81 <https://www.jstor.org/stable/4481569>.
- [4] Ballhausen B, Kriegeskorte A, Schleimer N, Peters G, Becker K. The *mecA* homolog *mecC* confers resistance against β -lactams in *Staphylococcus aureus* irrespective of the genetic strain background. Antimicrob Agents Chemother 2014;58(7):3791–8, <http://dx.doi.org/10.1128/AAC.02731-13>.

- [5] Reichmann NT, Pinho MG. Role of SCCmec type in resistance to the synergistic activity of oxacillin and cefoxitin in MRSA. *Sci Rep* 2017;7(1):6154. <http://dx.doi.org/10.1038/s41598-017-06329-2>.
- [6] Wu Z, Li F, Liu D, Xue H, Zhao X. Novel type XII Staphylococcal Cassette Chromosome mec harboring a new Cassette Chromosome Recombinase, Ccr2. *Antimicrob Agents Chemother* 2015;59(12):7597–601. <http://dx.doi.org/10.1128/AAC.01692-15>.
- [7] Baig S, Johannesen TB, Ovarballe-Petersen S, Larsen J, Larsen AR, Stegger M. Novel SCCmec type XIII (9A) identified in an ST152 methicillin-resistant *Staphylococcus aureus*. *Infect Genet Evol* 2018;61:74–6. <http://dx.doi.org/10.1016/j.meegid.2018.03.013>.
- [8] Armand-Lefevre L, Ruimy R, Andrement A. Clonal comparison of *Staphylococcus aureus* isolates from healthy pig farmers, human controls, and pigs. *Emerg Infect Dis* 2005;11(5):711–4. <http://dx.doi.org/10.3201/eid1105.040866>.
- [9] Voss A, Loeffen F, Bakker J, Klaassen C, Wulf M. Methicillin-resistant *Staphylococcus aureus* in pig farming. *Emerg Infect Dis* 2005;11(12):1965–6. <http://dx.doi.org/10.3201/eid1112.050428>.
- [10] Petersen A, Stegger M, Heltberg O, Christensen J, Zeuthen A, Knudsen LK, et al. Epidemiology of methicillin-resistant *Staphylococcus aureus* carrying the novel *mecC* gene in Denmark corroborates a zoonotic reservoir with transmission to humans. *Clin Microbiol Infect* 2013;19(1):E16–22. <http://dx.doi.org/10.1111/1469-0691.12036>.
- [11] Ariza-Miguel J, Hernández M, Fernández-Natal I, Rodríguez-Lázaro D. Methicillin-resistant *Staphylococcus aureus* harboring *mecC* in livestock in Spain. *J Clin Microbiol* 2014;52(11):4067–9. <http://dx.doi.org/10.1128/JCM.01815-14>.
- [12] Paterson GK, Morgan FJ, Harrison EM, Cartwright EJ, Török ME, Zadoks RN, et al. Prevalence and characterization of human *mecC* methicillin-resistant *Staphylococcus aureus* isolates in England. *J Antimicrob Chemother* 2014;69(4):907–10. <http://dx.doi.org/10.1093/jac/dkt462>.
- [13] Paterson GK, Harrison EM, Holmes MA. The emergence of *mecC* methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol* 2014;22(1):42–7. <http://dx.doi.org/10.1016/j.tim.2013.11.003>.
- [14] García-Álvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, et al. Methicillin-resistant *Staphylococcus aureus* with a novel *mecA* homologue in human and bovine populations in the UK and Denmark: a descriptive study. *Lancet Infect Dis* 2011;11(8):595–603. [http://dx.doi.org/10.1016/S1473-3099\(11\)70126-8](http://dx.doi.org/10.1016/S1473-3099(11)70126-8).
- [15] García-Garrote F, Cercenado E, Marín M, Bal M, Trincado P, Corredoira J, et al. Methicillin-resistant *Staphylococcus aureus* carrying the *mecC* gene: emergence in Spain and report of a fatal case of bacteraemia. *J Antimicrob Chemother* 2014;69(1):45–50. <http://dx.doi.org/10.1093/jac/dkt327>.
- [16] Harrison EM, Paterson GK, Holden MT, Larsen J, Stegger M, Larsen AR, et al. Whole genome sequencing identifies zoonotic transmission of MRSA isolates with the novel *mecA* homologue *mecC*. *EMBO Mol Med* 2013;5(4):509–15. <http://dx.doi.org/10.1002/emmm.201202413>.
- [17] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-seventh edition Wayne, PA: CLSI; 2018 (Document M100-S28). <https://iaclid.org/DL/public/CLSI-2018-M100-S28.pdf>.
- [18] Sambrook J, Russell DW. Transcriptional run-on assays. *CSH Protoc* 2006;2006(1). <http://dx.doi.org/10.1101/pdb.prot3956>, pii: pdb.prot3956.
- [19] Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the *mec* element in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2002;46(7):2155–61. <http://dx.doi.org/10.1128/AAC.46.7.2155-2161.2002>.
- [20] Stegger M, Andersen PS, Kearns A, Pichon B, Holmes MA, Edwards G, et al. Rapid detection, differentiation and typing of methicillin-resistant *Staphylococcus aureus* harbouring either *mecA* or the new *mecA* homologue *mecA*(LGA251). *Clin Microbiol Infect* 2012;18(4):395–400. <http://dx.doi.org/10.1111/j.1469-0691.2011.03715.x>.
- [21] Cikman A, Aydin M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, et al. Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant *Staphylococcus aureus* isolates: a multi-center study. *Mikrobiyol Bul* 2015;49(2):240–8. <http://dx.doi.org/10.5578/mb.9230>.
- [22] Coban AY. Rapid determination of methicillin resistance among *Staphylococcus aureus* clinical isolates by colorimetric methods. *J Clin Microbiol* 2012;50(7):2191–3. <http://dx.doi.org/10.1128/JCM.00471-12>.
- [23] Skoy R, Larsen AR, Kearns A, Holmes M, Teale C, Edwards G, et al. Phenotypic detection of *mecC*-MRSA: cefoxitin is more reliable than oxacillin. *J Antimicrob Chemother* 2014;69(1):133–5. <http://dx.doi.org/10.1093/jac/dkt341>.
- [24] Datta P, Gulati B, Singla N, Rani Vasdeva H, Bala K, Chander J, et al. Evaluation of various methods for the detection of methicillin-resistant *Staphylococcus aureus* strains and susceptibility patterns. *J Med Microbiol* 2011;60(Pt 11):1613–6. <http://dx.doi.org/10.1099/jmm.0.032219-0>.
- [25] David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic. *Clin Microbiol Rev* 2010;23(3):616–87. <http://dx.doi.org/10.1128/CMR.00081-09>.
- [26] Kong EF, Johnson JK, Jabra-Rizk MA. Community-associated methicillin-resistant *Staphylococcus aureus*: an enemy amidst us. *PLoS Pathog* 2016;12(10):e1005837. <http://dx.doi.org/10.1371/journal.ppat.1005837>.
- [27] Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect* 2007;13(3):222–35. <http://dx.doi.org/10.1111/j.1469-0691.2006.01573.x>.
- [28] Akoğlu H, Zzarakolu P, Altun B, Ünal S. Epidemiological and molecular characteristics of hospital-acquired methicillin-resistant *Staphylococcus aureus* strains isolated in Hacettepe University Adult Hospital in 2004–2005. *Mikrobiyol Bul* 2010;44(3):343–55.
- [29] Kiliç A, Guclu AU, Senses Z, Bedir O, Aydoğan H, Basustaoglu AC. Staphylococcal cassette chromosome *mec* (SCCmec) characterization and panton-valentine leukocidin gene occurrence for methicillin-resistant *Staphylococcus aureus* in Turkey, from 2003 to 2006. *Antoni Van Leeuwenhoek* 2008;94(4):607–14. <http://dx.doi.org/10.1007/s10482-008-9278-3>.
- [30] Bozdogan B, Yıldız O, Oryaşın E, Kırdar S, Gülcü B, Aktepe O, et al. t030 is the most common spa type among methicillin-resistant *Staphylococcus aureus* strains isolated from Turkish hospitals. *Mikrobiyol Bul* 2013;47(4):571–81. <http://dx.doi.org/10.5578/mb.5770>.
- [31] Ma XX, Ito T, Chongtrakool P, Hiramatsu K. Predominance of clones carrying Pantone-Valentine leukocidin genes among methicillin-resistant *Staphylococcus aureus* strains isolated in Japanese hospitals from 1979 to 1985. *J Clin Microbiol* 2006;44(12):4515–27. <http://dx.doi.org/10.1128/JCM.00985-06>.
- [32] Basset P, Prod'homme G, Senn L, Greub G, Blanc DS. Very low prevalence of methicillin-resistant *Staphylococcus aureus* carrying the *mecC* gene in western Switzerland. *J Hosp Infect* 2013;83(3):257–9. <http://dx.doi.org/10.1016/j.jhin.2012.12.004>.
- [33] Schaumburg F, Köck R, Mellmann A, Richter L, Hasenberg F, Kriesgeskorte A, et al. Population dynamics among methicillin-resistant *Staphylococcus aureus* isolates in Germany during a 6-year period. *J Clin Microbiol* 2012;50(10):3186–92. <http://dx.doi.org/10.1128/JCM.01174-12>.
- [34] Ganesan A, Crawford K, Mende K, Murray CK, Lloyd B, Ellis M, et al. Evaluation for a novel methicillin resistance (*mecC*) homologue in methicillin-resistant *Staphylococcus aureus* isolates obtained from injured military personnel. *J Clin Microbiol* 2013;51(9):3073–5. <http://dx.doi.org/10.1128/JCM.01516-13>.
- [35] Khairalla AS, Wasfi R, Ashour HM. Carriage frequency, phenotypic, and genotypic characteristics of methicillin-resistant *Staphylococcus aureus* isolated from dental health-care personnel, patients, and environment. *Sci Rep* 2017;7(1):7390. <http://dx.doi.org/10.1038/s41598-017-07713-8>.
- [36] Saeed K, Ahmad N, Dryden M, Cortes N, Marsh P, Sitiari A. Oxacillin-susceptible methicillin-resistant *Staphylococcus aureus* (OS-MRSA), a hidden resistant mechanism among clinically significant isolates in the Wessex region/UK. *Infection* 2014;42(5):843–7. <http://dx.doi.org/10.1007/s15010-014-0641-1>.
- [37] Kiliç A, Doğan E, Kaya S, Baysallar M. Investigation of the presence of *mecC* and Pantone-Valentine leukocidin genes in *Staphylococcus aureus* strains isolated from clinical specimens during seven years period. *Mikrobiyol Bul* 2015;49(4):594–9. <http://dx.doi.org/10.5578/mb.9871>.
- [38] Becker K, van Alen S, Idelevich EA, Schleimer N, Seggewiß J, Mellmann A, et al. Plasmid-encoded transferable *mecB*-mediated methicillin resistance in *Staphylococcus aureus*. *Emerg Infect Dis* 2018;24(2):242–8. <http://dx.doi.org/10.3201/eid2402.171074>.
- [39] Lakhundi S, Zhang K. Methicillin-resistant *Staphylococcus aureus*: molecular characterization, evolution, and epidemiology. *Clin Microbiol Rev* 2018;31(4). <http://dx.doi.org/10.1128/CMR.00020-18>, pii: e00020-18.